Shiloh
Editor, Senior Moderator
Source: http://www.eurekalert.org/pub_releases/2012-10/acos-afo092712.php
Public release date: 1-Oct-2012
Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
American College of Surgeons
A form of small pox virus shows potential for treating triple-negative breast cancer
Combined oncolytic and antiangiogenic activity of new vacinnia virus kills TNBC tumors in mice
CHICAGO?Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City have shown that a new vaccinia virus, acting as both an oncolytic and anti-angiogenic agent, can enter and kill triple-negative breast cancer (TNBC) cells. Study findings presented today at the 2012 Annual Clinical Congress of the American College of Surgeons could lead to a more targeted therapy against this deadly form of breast cancer.
According to the medical literature, TNBC is a form of breast cancer that is responsible for 10 to 20 percent of all breast cancer cases.* TNBC is most likely to occur in younger women (<35 years old), especially if they are African American or Hispanic. It is difficult to treat because women with TNBC lack three types of receptors?estrogen, progesterone, and HER2?that would allow them to benefit from existing hormonal and immune therapies. Although women diagnosed with TNBC, especially in later stages, do initially respond to chemotherapy, these tumors tend to be more aggressive and more likely to recur...
Public release date: 1-Oct-2012
Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
American College of Surgeons
A form of small pox virus shows potential for treating triple-negative breast cancer
Combined oncolytic and antiangiogenic activity of new vacinnia virus kills TNBC tumors in mice
CHICAGO?Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City have shown that a new vaccinia virus, acting as both an oncolytic and anti-angiogenic agent, can enter and kill triple-negative breast cancer (TNBC) cells. Study findings presented today at the 2012 Annual Clinical Congress of the American College of Surgeons could lead to a more targeted therapy against this deadly form of breast cancer.
According to the medical literature, TNBC is a form of breast cancer that is responsible for 10 to 20 percent of all breast cancer cases.* TNBC is most likely to occur in younger women (<35 years old), especially if they are African American or Hispanic. It is difficult to treat because women with TNBC lack three types of receptors?estrogen, progesterone, and HER2?that would allow them to benefit from existing hormonal and immune therapies. Although women diagnosed with TNBC, especially in later stages, do initially respond to chemotherapy, these tumors tend to be more aggressive and more likely to recur...